Health professionals: Applying for extended access to CGM and Flash GM products
In certain circumstances, extended access to the CGM Initiative through the NDSS may be granted for women with type 1 diabetes who are actively planning pregnancy.
Women with type 1 diabetes who are actively planning pregnancy
Women with type 1 diabetes actively planning pregnancy are eligible for access to CGM and Flash GM products for a period up to 12 months (initial period of 6 months with a subsequent period of an additional 6 months on confirmation—by an authorised health professional—that pre-pregnancy care is continuing).
Supporting documentation certified by an authorised health professional is mandatory for the review of any extended access application.
- Helpful hints for providing supporting documentation for extended access applications
(for planning pregnancy type 1 diabetes)
Indications for use
The CGM and Flash GM device summary and compatibility chart contains information about devices fully subsidised through the CGM Initiative as part of the NDSS, their compatibility with insulin pumps and smartphones and smart devices, and links to guidelines about appropriate use, including manufacturers documentation.
The Therapeutic Goods Administration approves CGM and Flash GM devices that can be lawfully supplied in Australia and these are listed in the Australian Register of Therapeutic Goods (ARTG).
By certifying Continuous and flash glucose monitoring eligibility assessment forms for a person, you are confirming that you are aware that not all CGM and Flash GM products are indicated for use in all conditions or all age groups, and that you have considered available advice about the selected device. This includes advice on the relevant ARTG listing about appropriate use for specific conditions.
The CGM and Flash GM device summary and compatibility chart contains links to the ARTG listings.